Breaking the Cycle: Unraveling the Diagnostic, Pathophysiological and Treatment Challenges of Refractory Migraine [PDF]
Frontiers in Neurology, 2023 BackgroundRefractory migraine is a poorly described complication of migraine in which migraine has chronified and become resistant to standard treatments.
Jennifer V Robblee
exaly +4 more sources
Resistant and Refractory Migraine: Clinical Presentation, Pathophysiology, and Management [PDF]
EBioMedicineSummary: Migraine is a leading cause of disability worldwide. A minority of individuals with migraine develop resistant or refractory conditions characterised by ≥ 8 monthly days of debilitating headaches and inadequate response, intolerance, or ...
Raffaele Ornello +2 more
exaly +4 more sources
Monocentric Prospective Study Into the Sustained Effect of Incobotulinumtoxin a (XEOMIN®) Botulinum Toxin in Chronic Refractory Migraine [PDF]
Toxins, 2018 Refractory chronic migraine is a disabling disorder impacting quality of life. BOTOX® (Onabotulinumtoxin A) is approved as a prophylactic treatment of chronic migraine in patients unresponsive to at least three prior preventive treatments.
Alessandro Lozza +2 more
exaly +4 more sources
Burden and attitude to resistant and refractory migraine: a survey from the European Headache Federation with the endorsement of the European Migraine & Headache Alliance [PDF]
The Journal of Headache and Pain, 2021 Background New treatments are currently offering new opportunities and challenges in clinical management and research in the migraine field. There is the need of homogenous criteria to identify candidates for treatment escalation as well as of reliable ...
Simona Sacco +14 more
doaj +2 more sources
Identifying and managing refractory migraine: barriers and opportunities? [PDF]
The Journal of Headache and Pain, 2019 The term refractory migraine has been used to describe persistent headache that is difficult to treat or fails to respond to standard and/or aggressive treatments.
Linda D’Antona, Manjit Matharu
doaj +2 more sources
Additive Interaction Between Onabotulinumtoxin-A and Erenumab in Patients With Refractory Migraine [PDF]
Frontiers in Neurology, 2021 In the last decade, notable progresses have been observed in chronic migraine preventive treatments. According to the European Headache Federation and national provisions, onabotulinumtoxin-A (BTX-A) and monoclonal antibodies acting on the pathway of ...
Marcello Silvestro +5 more
doaj +2 more sources
Erenumab in highly therapy-refractory migraine patients: First German real-world evidence [PDF]
The Journal of Headache and Pain, 2020 Background Calcitonin gene related peptide (CGRP) monoclonal antibodies (mAB) are the first specific migraine prophylactic medication. Erenumab is the only CGRP mAB targeting the CGRP receptor.
Armin Scheffler +7 more
doaj +2 more sources
Resistant and refractory migraine – two different entities with different comorbidities? Results from the REFINE study [PDF]
The Journal of Headache and PainBackground Resistant and refractory migraine are commonly encountered in specialized headache centers. Several comorbidities, mostly psychiatric conditions, have been linked to migraine worsening; however, there is little knowledge of the comorbidity ...
C. Rosignoli +31 more
doaj +2 more sources
European headache federation consensus on the definition of resistant and refractory migraine [PDF]
The Journal of Headache and Pain, 2020 Introduction Despite advances in the management of headache disorders, some patients with migraine do not experience adequate pain relief with acute and preventive treatments.
Simona Sacco +12 more
doaj +2 more sources
Peripheral Nerve Blocks in Adolescents with Medically Refractory Migraine: A Retrospective Observational Study [PDF]
ChildrenObjective: To evaluate the efficacy and safety of peripheral nerve blocks (PNB) in adolescents with medically refractory migraine. Materials and Methods: Twenty-eight adolescents with inadequate response to preventive therapy were included.
Hamit Acer, Beste Kipcak Yuzbasi
doaj +2 more sources